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Background: Although amiodarone (AMD) is applied for implantable cardioverter-
deﬁbrillator (ICD) patients to reduce VT/VF events, its actual beneﬁt and long-term eﬃcacy
are unclear. In the present study, we retrospectively evaluated the incidence of VT/VF events
in ICD patients with and without AMD.
Methods and results: The study population consisted of 77 consecutive patients with ICD
therapy and structural heart diseases. They were followed up for 24 3 months, and the
incidences of VT/VF events or hospitalization were evaluated. When they were divided into
two groups with and without VT/VF events (42:35), univariate analysis indicated a higher
incidence of cardiomyopathy as the basic disease, VT as the initial arrhythmic diagnosis,
higher levels of total bilirubin, and a lower incidence of AMD use in patients with VT/VF
events. When they were divided by AMD use (24/53), VT/VF events were observed in 8/24
in patients with AMD (33.3%) and 34/53 without AMD (64.2%, p ¼ 0:012). In sub-group
analysis based on left ventricular ejection function (LVEF), the VT/VF event rate was lower
in the AMD group in patients with LVEF < 40% (p ¼ 0:007).
Conclusions: AMD was considered to reduce VT/VF events in ICD patients, especially in
the population with structural heart disease and lower LVEF.
(J Arrhythmia 2010; 26: 250–258)
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Introduction
Many clinical studies have demonstrated the
superiority of implantable cardioverter-deﬁbrillator
(ICD) therapy over antiarrhythmic drug therapy for
the prevention of sudden cardiac death both in
primary and secondary prevention.1–5) Therefore,
ICD therapy has been recommended as fundamental
therapy, especially for secondary prevention of life-
threatening ventricular arrhythmias as given in device
therapy guidelines.6) However, because ICD is not a
preventive therapy for ventricular tachycardia (VT)
or ventricular ﬁbrillation (VF), additional preventive
therapy is necessary to decrease the chance of ICD
shock delivery. As well as catheter ablation, antiar-
rhythmic agents are an option for VT/VF prevention
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but their indications are limited when negative
inotropic action or proarrhythmia are considered,
especially in patients with organic heart diseases.
Although amiodarone (AMD) may cause various
clinical side eﬀects, such as interstitial pneumonia,
thyroid abnormality, etc.,7) this medicine is now
widely used in clinical practice because many studies
have documented that AMD is at least one of the
strongest antiarrhythmic agents to control VT/VF,8,9)
and even more importantly, acts without causing
ventricular dysfunction or proarrhythmia.10) Recent-
ly, the OPTIC study showed that AMD reduced ICD
shocks more eﬀectively than sotalol or beta-blockers,
especially in the ﬁrst year after ICD implantation,
although the number of patients in the study was
limited.11) The NIPPON study has also indicated the
usefulness of AMD to reduce ICD shocks12) but the
long-term beneﬁt of empirical AMD use in ICD
patients should be evaluated in longer observation. In
the present study, we retrospectively analyzed the
usefulness of AMD to reduce ICD shocks in ICD
patients with organic heart disease in our institute.
Methods
Study population
The study population consisted of 77 patients
receiving ICD therapy for any type of structural
heart diseases. They were selected from 151 con-
secutive ICD patients followed up in our institute.
Sixty-nine patients without structural heart diseases,
e.g., Brugada syndrome, idiopathic ventricular ta-
chycardia, long QT syndrome, etc., and 5 patients
under unstable basic disease, e.g., severe heart
failure, were excluded from analysis in this study.
The mean age was 60 2 years, 15 were female and
62 were male. The basic structural heart disease was
ischemic heart disease in 40, idiopathic dilated
cardiomyopathy in 23, idiopathic hypertrophic car-
diomyopathy in 4, and other conditions in the
remaining 10 patients. All patients underwent an
echocardiogram and cardiac catheterization, and the
diagnosis of structural heart disease was made based
on the ﬁndings of coronary angiography and left
ventriculography in all cases, and left ventricular
myocardial biopsy in selected cases (n ¼ 28). All
studies, including retrospective analyses, were per-
formed after obtaining written informed consent and
permission from the Clinical Studies and Ethics
Committee of Kitasato University Hospital.
Diagnosis of arrhythmia and indications for ICD
therapy and/or AMD
The indication for ICD therapy was determined
based on the guidelines for non-pharmacological
therapy of cardiac arrhythmias (The Japanese Cir-
culation Society 2006).6) Table 1 shows the clinical
characteristics of the 77 patients; 45 and 24 patients
exhibited episodes of spontaneous VT and VF,
respectively, and ICD was implanted for secondary
prevention of VT/VF, regardless of the attempt or
result of catheter ablation. So-called ‘‘Electrophysio-
logic study (EPS)-guided pharmacological thera-
py’’13) was attempted only in selected cases (n ¼ 3)
by using class I antiarrhythmic agents, i.e., mexile-
tine in 1 and procainamide in 2 patients. In the
remaining 8 patients, ICD was implanted for primary
prevention of VT/VF. The determinants of ICD
implantation were 1) left ventricular dysfunction and
non-sustained VT (NSVT) in 3, 2) NSVT and
inducible sustained VT/VF in EPS in 3, 3) left
ventricular dysfunction and history of syncope in 1,
and 4) history of syncope and inducible sustained
VT/VF in EPS in 1 patient.
The retrospective observation was principally
started at the time of the ICD implantation, but in
patients in whom AMD administration was started
after the ICD implantation, the observation was
started at starting time of AMD administration.
There were no exact criteria for administration of
AMD because the present study was based on
retrospective observation. Therefore, AMD was
prescribed for each patient for individual reasons
but mainly for suppression of frequent NSVT or
sustained VT/VF during initial hospitalization or
ICD shocks after ICD implantation. AMD, which
was prescribed for the purpose of suppression of
frequent premature ventricular contraction (PVC) or
NSVT before ICD implantation, was discontinued at
the time of ICD implantation if frequent PVC or
NSVT was not observed. When AMD was already
prescribed before transferring the patient from the
previous hospital to our institute, AMD was not
discontinued even if NSVT was not observed. In
selected cases, other class III antiarrhythmic agents
were prescribed for the same purpose as AMD, i.e.,
d,l-sotalol in 8 and bepridil in 3 patients. In patients
with AMD, the initial loading dose was set at
400mg/day for 2 weeks and the maintenance dose
was set at 200mg/day. In a selected patient with
slight liver dysfunction (n ¼ 1), the maintenance
dose was set at 100mg/day. The side eﬀects of
AMD were ruled out by repeating ECG recording,
chest X-ray, measurement of KL-6, T3, and T4 every
2–3 months.14,15)
Detection of clinical events and data analysis
The clinical events were retrospectively analyzed
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in each patient during the follow up period of 24 3
months (range, 3 to 102 months). The primary
endpoint in this retrospective observation was a fatal
arrhythmic event, which was deﬁned by the appro-
priate delivery of ICD therapy for VT/VF. Inappro-
priate ICD shock delivery caused by supraventricular
tachycardia, device malfunction, etc., were not
counted as arrhythmic events. The classiﬁcation as
appropriate or inappropriate delivery was made
based on the analysis of the recording retrieved
from the ICD memory, including heart rate, rate
variability, EGM morphology and relationship be-
tween atrial and ventricular electrograms.12) The
secondary endpoint in this study was re-hospital-
ization during the follow-up period, which mainly
occurred as a result of worsening heart failure or
basic heart disease.
Data analysis
First, the 77 patients were divided into two groups
based on the presence or absence of appropriate ICD
therapy, i.e., VT/VF episode during the follow-up
period, and patient data, including clinical character-
istics and therapies, were compared between the two
groups to ﬁnd predictors or determinants of future
VT/VF episodes.
Second, the patients were divided into two groups
based on whether they were given AMD, and the
incidence of VT/VF episodes and re-hospitalization
episodes during the follow-up period were compared
between the two groups by Kaplan-Meyer analysis.
The comparison of event rates between the AMD
and non-AMD group was also performed in sub-
groups with severe left ventricular dysfunction (left
ventricular ejection fraction: LVEF < 40%) and
others.
Statistical analysis
All statistical analyses were performed using one-
way ANOVA and the Kaplan-Meier survival curve,
or the t-test using statistical software JMP (SAS
Institute Inc., Cary, NC, USA). To evaluate predic-
tors of clinical events, uni- and multivariate analyses
were performed. The values are presented as the
mean  standard deviation. p < 0:05 was consid-
ered signiﬁcant.
Table 1 Clinical characteristics of ICD patients with structural heart disease
Total
n ¼ 77
AMD group
n ¼ 24 (31%)
Non-AMD group
n ¼ 53 (69%) p value
Age (years) 60 2 57 3 62 2 0.248
Gender (Female: Male) 15:62 6:18 9:44 0.411
Mean follow-up period (months) 24 3 27 5 22 3 0.428
Basic diseases (Ischemic heart disease/Cardiomyopathy/Others) 40/27/10 14/8/2 26/19/8 0.643
Diagnosis of arrhythmia (VT/VF/Others) 45/24/8 13/6/5 32/18/3 0.123
History of electrical storm 12 (16%) 5 (21%) 7 (13%) 0.393
History of non-sustained VT 65 (90%) 20 (87%) 45 (92%) 0.515
EPS-guided risk evaluation (High risk/Low risk/Unknown) 14/7/56 6/2/16 8/5/40 0.580
EPS-guided pharmacological therapy 3 (4%) 1 (4%) 2 (4%) 0.9342
Cardio-thoracic ratio (%) 59 1 56 1 56 1 0.790
Left ventricular ejection fraction (%) 38 1 36 2 39 2 0.244
Brain natriuretic peptide (pg/mL) 295 37 232 61 317 45 0.270
Total bilirubin (mg/dL) 0.59  0.03 0.53  0.06 0.62  0.04 0.249
Serum creatinine (mg/dL) 1.3  0.2 1.1  0.1 1.3  0.2 0.341
Class I antiarrhythmic drugs 9 (12%) 2 (8%) 7 (13%) 0.538
Amiodarone 24 (31%)
D,l-sotalol 8 (10%) 0 (0%) 8 (15%) 0.044
Bepridil 3 (4%) 0 (0%) 3 (6%) 0.235
ARB/ACE-I 64 (83%) 22 (92%) 42 (80%) 0.178
Beta-blockers 47 (61%) 16 (66%) 31 (58%) 0.496
Digoxin 20 (26%) 7 (29%) 13 (25%) 0.667
Diuretics 58 (75%) 19 (79%) 39 (74%) 0.599
AMD indicates amiodarone, VT: ventricular tachycardia, VF: ventricular ﬁbrillation, EPS: electrophysiological study, ARB:
angiotensin receptor blocker, and ACE-I: angiotensin-converting enzyme inhibitor.
indicates statistically signiﬁcant diﬀerences between groups with and without AMD.
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Results
Clinical events during the follow-up period
During the follow-up period of 24 3 months
(range, 3 to 102 months), appropriate ICD therapy,
i.e., VT/VF events, was observed in 42/77 patients
(55%) and re-hospitalization events were observed
in 27/77 patients (35%). No patients suﬀered
sudden cardiac death but 4 patients died due to
worsening heart failure. The other 3 patients died
due to non-cardiac causes. In 24/77 patients with
AMD therapy, no patient suﬀered severe side
eﬀects of AMD, such as interstitial pneumonia,
but 2/24 patients exhibited slight hypothyroidism,
which subsided after post-study withdrawal of
AMD, without any speciﬁc therapy. AMD was
discontinued in one patient because of KL-6
elevation. In the remaining patients, AMD was
continued with the same maintenance dose during
the follow-up period.
Comparison of patients with and without VT/VF
events
Table 2 shows the comparison of clinical param-
eters between patients with and without VT/VF
events during the follow-up period. There were no
signiﬁcant diﬀerences between the two groups in
terms of age, gender, follow-up period, history of
electrical storm, history of NSVT, EPS-guided risk
evaluation, cardio-thoracic ratio (CTR), LVEF, brain
natriuretic peptide (BNP), and serum creatinine,
although LVEF and BNP tended to be higher in
patients with VT/VF events than in those without
events. In contrast, the incidence of cardiomyopathy
as the basic disease, VT as the initial diagnosis of
arrhythmia, and total bilirubin levels were higher in
patients with VT/VF events than in those without
events. As pharmacological therapy, various drugs
for heart failure were used in both groups of patients
with and without VT/VF events. There were no
signiﬁcant diﬀerences in the use of ARB/ACE-I,
beta-blocker, diuretics and digoxin between the two
Table 2 Uni- and multivariate analyses of comparison of patients with and without VT/VF events
With VT/VF Without VT/VF Univariate Multivariate
events (n ¼ 42) events (n ¼ 35) p value 95% CI Odds ratio p value
Age (years) 60 2 61 3 0.682
Gender (Female: Male) 10:32 5:30 0.293
Mean follow-up period (months) 21 3 28 4 0.154
Basic diseases (Ischemic heart 19 8 0.029 0.03421.2128 3.08 0.073
disease/Cardiomyopathy/Others)
Diagnosis of arrhythmia
(VT/VF/Others) 11 13 0.011
 0.25921.4310 5.07 0.006
History of electrical storm 6 (14%) 6 (17%) 0.731
History of non-sustained VT 38 (93%) 27 (87%) 0.428
EPS-guided risk evaluation
(High risk/Low risk/Unknown) 9/5/28 5/2/28 0.405
Cardio-thoracic ratio (%) 56 1 56 =1 0.670
Left ventricular ejection fraction (%) 37 2 40 2 0.272
Brain natriuretic peptide (pg/mL) 343 55 231 44 0.116
Total bilirubin (mg/dL) 0.67  0.05 0.50  0.04 0.009 0.10384.1778 13.29 0.084
Serum creatinine (mg/dL) 1.4  0.3 1.1  0.1 0.363
Class I antiarrhythmic drugs 5 (12%) 4 (11%) 0.948
Amiodarone 8 (19%) 16 (46%) 0.012 0.08341.2775 3.73 0.029
D,l-sotalol 5 (12%) 3 (9%) 0.631
Bepridil 1 (2%) 2 (6%) 0.452
ARB/ACE-I 35 (83%) 29 (83%) 0.956
Beta-blockers 23 (55%) 24 (69%) 0.216
Digoxin 11 (26%) 9 (26%) 0.962
Diuretics 32 (76%) 26 (74%) 0.847
VT indicates ventricular tachycardia, VF: ventricular ﬁbrillation, EPS: electrophysiological study, ARB: angiotensin receptor
blocker, and ACE-I: angiotensin-converting enzyme inhibitor.
indicates statistically signiﬁcant diﬀerences between groups with and without VT/VF events.
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groups. The use of antiarrhythmic agents of d,l-
sotalol, bepridil and class I agents also did not diﬀer
between the two groups, but AMD use was higher in
patients without VT/VF events than with events.
Table 2 also exhibits uni- and multivariate analyses
of the clinical parameters for the prediction of VT/
VF events during the follow-up period. Univariate
analysis showed cardiomyopathy as the basic dis-
ease, VT as the initial diagnosis of arrhythmia, and
higher levels of total bilirubin and non-administra-
tion of AMD as signiﬁcant predictors of VT/VF
events. In contrast, in multivariate analysis, VT as
the initial diagnosis of arrhythmia and non-admin-
istration of AMD were the only independent sig-
niﬁcant predictors of VT/VF events.
Comparison of patients with and without AMD
therapy
Out of 77 patients, AMD was prescribed in 24
patients (31%) during the follow-up period and the
patients were divided into two groups with and
without AMD therapy, i.e., AMD and non-AMD
groups. Basic comparison of the clinical data of two
groups at starting of observation is shown in Table 1.
There were no signiﬁcant diﬀerences between the
two groups in clinical characteristics, except for the
use of class III antiarrhythmic agents. The incidence
of VT/VF or NSVT events during the follow-up
period is shown in Table 3. The incidence of VT/VF
events was signiﬁcantly higher in the non-AMD
group than the AMD group (p ¼ 0:012). Figure 1
shows Kaplan-Meyer curves for VT/VF events
in AMD and non-AMD groups. During this obser-
vation, the VT/VF event rate was signiﬁcantly
higher in the non-AMD group than the AMD group.
Interestingly, this diﬀerence became clear after 1 to
2 years of observation and there seemed to be no
diﬀerence between the two groups in the initial year.
Figure 2 shows Kaplan-Meyer curves for re-hospital-
ization events in AMD and non-AMD groups. In
contrast to VT/VF events, there was no diﬀerence
between the two groups along the time course.
Figure 3 shows the comparison of VT/VF event
rates between AMD and non-AMD groups in all
patients and in subgroups of patients with LVEF <
40% and =40%. In all patients, the VT/VF event
rate was higher in the non-AMD group than in the
AMD group, and this was also true in subgroup
patients with lower LVEF, i.e., LVEF < 40%. In
contrast, in patients with LVEF = 40%, the diﬀer-
ence between groups became insigniﬁcant.
Discussion
This study, evaluating VT/VF events or re-
hospitalization events in ICD patients with structural
heart disease, has documented several interesting
points. First, VT as the initial diagnosis of arrhyth-
mia and no use of AMD were considered to be
independent risk factors predicting VT/VF events.
Second, the VT/VF event rate was signiﬁcantly
lower in patients with AMD than without AMD, but
the re-hospitalization event rate was not. The diﬀer-
ence in the VT/VF event rate became signiﬁcant
after 1 to 2 years of observation but not in the ﬁrst
year. Finally, reduction of the VT/VF event rate by
AMD therapy was observed in all and subgroup
patients with low LVEF, but not in patients without
LV dysfunction.
Factors predicting VT/VF events in ICD patients
Although ICD therapy may highly guarantee
recovery from fatal arrhythmia, their shocks may
have several adverse eﬀects clinically. Some studies
revealed that ICD shocks increased the risk of
myocardial injury,16,17) and it may result in a higher
risk for cardiac death than similar patients without
shocks.18) Although ICD shocks might be just a
marker for worsening basic structural disease in such
observations, ICD shocks should be avoided as much
as possible from the point of view of patients’ QOL.19)
Several studies have reported that low LVEF, high
BNP, lack of eﬀective preventive therapy, mono-
morphic VT, inducible sustained VT/VF in EPS and
conventional class I antiarrhythmic drug therapy are
risk factors for future VT/VF events in ICD patients
with structural heart disease.20–23) In our observation,
although LVEF or BNP data tended to exhibit a
similar tendency as previous reports, they were not
signiﬁcant and only VT as the initial diagnosis of
arrhythmia and no use of AMD were signiﬁcant
predictors of VT/VF events. These insigniﬁcant
Table 3 VT/VF or non-sustained VT events in patients with and without AMD therapy during the follow-up period
AMD group n ¼ 24 (31%) Non-AMD group n ¼ 53 (69%) p value
VT/VF events 8 (33%) 34 (64%) 0.012
Non-sustained VT events 12 (57%) 43 (83%) 0.022
AMD indicates amiodarone, VT: ventricular tachycardia, VF: ventricular ﬁbrillation.
indicates statistically signiﬁcant diﬀerences between groups with and without AMD.
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results probably resulted from the small study
population, but our study at least indicates that
initial diagnosis of arrhythmia and use of AMD are
important factors inﬂuencing future VT/VF events.
It has been reported that EPS-guided prevention
would be useful to reduce future arrhythmic events,
especially in secondary prevention of monomorphic
VT,13) but this factor was also not signiﬁcant in our
observation, probably because our study population
included primary prevention and VF patients. How-
ever, each predicting factor should be evaluated in
subgroups for diﬀerent diagnoses and purposes, i.e.,
primary and secondary prevention in a larger
population if possible.
Primary and secondary preventionx
Several reports have documented that the patients
with previous history of cardiac arrest or document-
ed VT would exhibit higher risk of VT/VF or
sudden cardiac death in comparison with those
without such events.24) In the present study, ICD
therapy was indicated in 8/77 patients as primary
prevention, and as secondary prevention in the
remaining 69 patients. As a result, the incidence of
VT/VF events was signiﬁcantly higher in the
patients with secondary prevention (primary 12.5%
vs. secondary 59.4%, p ¼ 0:0116), and the result
was quite compatible with the data from previous
reports. The administration of AMD was observed
in 5 (62.5%) in the primary prevention and in 19
(27.5%) in the secondary prevention patients, and
the VT/VF event in primary prevention was ob-
served in 1 patient without AMD administration.
Although it seems that AMD tended to suppress
VT/VF even for primary prevention, the statistical
comparison was not performed because the
number of the patients of primary prevention was
too small.
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Figure 1 Kaplan-Meyer curves for
VT/VF events
Figure 1 shows Kaplan-Meyer curves for
VT/VF events in the two groups (dotted
line shows the AMD group and solid line
shows the non-AMD group). During this
observation, the VT/VF event rate was
signiﬁcantly higher in the non-AMD group
than the AMD group. Interestingly, this
diﬀerence became obvious after 1 to 2
years of observation and there seemed to
be no diﬀerence between the two groups in
the initial year.
Figure 2 Kaplan-Meyer curves for re-
hospitalization events
Figure 2 shows Kaplan-Meyer curves for
re-hospitalization events in the two groups
(dotted line shows the AMD group and
solid line shows the Non-AMD group). The
re-hospitalization rate caused by cardiac
events was not diﬀerent between the two
groups during the time course.
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Effect of amiodarone in clinical use
Because this study was a retrospective observa-
tion, the medical decision-making process regarding
the use of AMD use was not always consistent.
Patients with AMD therapy in this study tended to
have a higher risk for ventricular arrhythmic events,
but the result was that patients with AMD therapy
exhibited signiﬁcantly fewer arrhythmic episodes
during observation, regardless of possible selection
bias of patients. In the basic comparison of the
patients, the AMD group tended to exhibit higher
incidence of patients with a history of the electrical
storm, but there was no statistical diﬀerence between
the AMD and non-AMD groups in terms of NSVT or
electrical storm history (Table 1). Diﬀerently from
the OPTIC study,11) the diﬀerence in the incidence of
VT/VF between AMD and non-AMD groups be-
came signiﬁcant after a relatively longer observation
period, i.e., more than 12–18 months, and the
diﬀerence became larger during the time course of
the observation (Figure 1). This ﬁnding is of interest
because it is the ﬁrst observation of the beneﬁt of the
empirical use of AMD for VT/VF prevention in ICD
patients. This may indicate that the VT/VF episodes
observed in this study did not result from prevention
failure or proarrhythmic eﬀects, but from the
progression of the basic structural disease with
construction of the arrhythmogenic substrate. Be-
cause several reports have suggested that AMD
will prevent the worsening of heart failure,10,25)
the results in this study might be a result of the
preventive eﬀect on ventricular dysfunction. Fur-
thermore, it has been reported that the eﬀects of
AMD on ion channels have two aspects, i.e., an
acute phase for sodium channel, L-type Ca channel
and Ikr channel, and a chronic phase for Iks, Ikur and
Ito channels and Na/K ATPase,26) so the late eﬀect
of AMD observed in this study might be a result of
the blocking eﬀects of potassium channels.
We have also conﬁrmed the diﬀerence between
AMD and non-AMD groups for VT/VF events in
patients with LV dysfunction (LVEF < 40%), but
not in patients without LV dysfunction (LVEF =
40%). This result was generally compatible with
previous reports,25,27) and is possibly explained by
the lower incidence of arrhythmic events in the
population with normal cardiac function. In accord-
ance with the results of this study, the beneﬁt of
AMD therapy for VT/VF prevention was more
enhanced in patients with LV dysfunction.
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Figure 3 The comparison of VT/VF event rates
Figure 3 shows the comparison of VT/VF event rates between AMD and non-AMD groups in all patients and
subgroups of patients with LVEF < 40% and =40%. In all patients, the VT/VF event rate was higher in the non-AMD
group than in the AMD group, and this was also true in subgroup patients with lower LVEF, i.e., LVEF < 40%. In
contrast in patients with LVEF = 40%, the diﬀerence between groups became insigniﬁcant.
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Although AMD therapy decreased the VT/VF
events in our observation, it did not aﬀect re-
hospitalization episodes. By considering the results
of the CAST study,28) antiarrhythmic drug therapy
should be considered to worsen basic structural heart
disease but it did not happen in this observation
because AMD is mainly a class III antiarrhythmic
agent. Although the heart failure-preventing eﬀect,
such as in the GESICA study,25) was not observed in
this study, the result seemed to be compatible with
various other reports.10,11,27) At least through our
observation, AMD might be considered to decrease
arrhythmic events without worsening the basic heart
condition.
Effect of the use of other class III antiarrhythmic
agents
There were some cases in which other class III
antiarrhythmic agents were prescribed to suppress
VT/VF in the non-AMD group, i.e., d,l-sotalol in 8
(15%) and bepridil in 3 (6%). Because these drugs
might exhibit a proarrhythmic eﬀect, inclusion of the
use of other antiarrhythmic agents only for the non-
AMD group may have indirectly overestimated the
suppressive eﬀect of AMD for VT/VF. Although the
use of these drugs did not aﬀect VT/VF events in the
present study, the eﬀect of the use of other antiar-
rhythmic agents should be re-evaluated with a
prospective study design.
Limitations
The present study has several limitations. First, the
number of patients in the observation was limited
because it was performed in a single institute.
Second, because this was a retrospective observa-
tion, the AMD use was not randomized. Third,
although we found no statistical diﬀerence in clinical
characteristics between patient groups with and
without AMD, subgroup analysis should be per-
formed by categorizing patients with diﬀerent
diagnoses of basic disease and/or arrhythmias.
Finally, the observation period was also limited in
this study. These points should be solved in future
studies involving more institutes, such as the
NIPPON study.
Conclusions
In this retrospective observation of ICD-implanted
patients, empiric AMD therapy reduced VT/VF
events in patients with structural heart disease. The
eﬀect of AMD to reduce VT/VF was more obvious
in patients with LV dysfunction. In Kaplan-Meyer
analysis, the eﬀect of AMD was insigniﬁcant in the
earlier phase of observation, but became signiﬁcant
in the later phase (12–18 months).
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